With respect to GC, clinical trials have demonstrated antitumor activity with PD‐1/PD‐L1 inhibitors,8 with the milestone clinical trial Checkmate 649 leading to the Food and Drug Administration approval of the PD‐1 inhibitor nivolumab for advanced or metastatic GC.9 Here, PDCD1 is linked to gastric cancer.